Pharmaceuticals
Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm
* Polytaxel, a novel pain-free anticancer drug, may not require break periods * A new standard of care, more convenient than docetaxel, is suggested * Hyundai Bioscience to enter clinical trial on pancreatic cancer in Australia * Patient-centered chemotherapy to enable outpatients to live nor...
2022-11-25 21:00
6904
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
SHANGHAI, Nov. 24, 2022 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its clinical trial application for 9MW3011 Injection used in patients with polycythemia vera was formally approved by the United States Food...
2022-11-24 21:00
3304
Jiangsu Traditional Chinese Medicine International Exchange Conference kicked off in Nanjing
NANJING, China, Nov. 23, 2022 /PRNewswire/ -- On November 21st, the "Jiangsu Traditional Chinese Medicine International Exchange Conference" jointly sponsored by the Foreign Affairs Office of Jiangsu Provincial People's Government and Jiangsu Health Commission kicked off inNanjing. The theme of t...
2022-11-23 14:19
1563
Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand
INDIANAPOLIS, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an ...
2022-11-22 20:00
1587
IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer
SYDNEY, Nov. 21, 2022 /PRNewswire/ -- Highlights * Clarity's fifth successful Investigational New Drug (IND) application with theUnited States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin * A total of six products with both the diagnostic and t...
2022-11-21 22:04
2856
Ainos Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals
VELDONA® interferon-alpha formulation has shown potential as a treatment candidate for feline chronic gingivostomatitis and canine atopic dermatitis Ainos advances its product pipeline as it targets commencing clinical studies during the second quarter of 2023 SAN DIEGO, Nov. 21, 2022 /PRNewswir...
2022-11-21 18:30
1182
Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics
CAMBRIDGE, Mass., Nov. 21, 2022 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution from "Idea to IND" ("I to ITM"), today announced that it has entered into a collaboration agreement with Dragonfly Therapeutics based on Nona...
2022-11-21 17:31
1205
Lianhua Respiratory Health Products to Assure the Smooth Holding of Hainan International Health Industry Expo
SHIJIAZHUANG, China, Nov. 21, 2022 /PRNewswire/ -- The 6th Hainan International Health Industry Expo kicked off onNovember 18th, in Haikou City, China's Hainan Province. With the theme of "Construct a Global Health System, Draw a Beautiful Future for Hainan Free Trade Port", this year's event wil...
2022-11-21 16:42
1255
MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea
- MEDICOX secures distribution right for ORAMED's oral insulin in South Korea after phase 3 of FDA approval - Contract scale up to 18 million dollars for developmental milestone and up to 15% royalty for sales - ORAMED says 1 in 7 Korean adults over 30 have diabetes and expects market potential ...
2022-11-18 17:11
1768
Standigm Synthetic Research Center successfully accelerates drug discovery in its first year
Lab uniquely enables collaboration between chemical and AI researchers
SEOUL, South Korea, Nov. 16, 2022 /PRNewswire/ -- Standigm
2022-11-17 08:45
1899
Simcere and Idorsia enter into a licensing agreement for daridorexant in China
NANJING, China, Nov. 15, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere"), an innovation and R&D-driven pharmaceutical company,and Idorsia Ltd (SIX: IDIA, "Idorsia"), specialized in the discovery, development and commercialization of small molecules to transform the hori...
2022-11-16 08:32
2199
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update
* Financial results for Q3 2022 ended with revenue of KRW 29.6 billion with continued growth in the pharmaceutical division driven by product portfolio expansion and strong sales in major products * R&D expenses for the quarter increased by 63%, reflecting the preparation of a Phase 3 study i...
2022-11-15 20:00
842
Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue
* Nabota exports grew significantly, achieving a 93.3% growth YOY, and overall revenue topsKRW 40.4 billion * Fexuclue, a new drug released last July, shows steep growth in market share in Korea * Nabota enters the European market and Fexuclue enters wide use as in prescriptions for gastrit...
2022-11-15 20:00
864
Nona Biosciences Announces Attendance at PEGS Europe 2022
CAMBRIDGE, Mass., Nov. 15, 2022 /PRNewswire/ -- Nona Biosciences (a wholly-owned subsidiary of HBM Holdings, HKEX: 02142) announced that the Company is attending the 14th Protein and Antibody Engineering Summit (PEGS) in Barcelona, Spain, November 14-16, 2022. The booth is located at #54. Frank ...
2022-11-15 15:57
1062
HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATION
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Harbor BioMed (HKEX: 02142) today announced establishment of a wholly-owned subsidiary, Nona Biosciences, to provide next-generation antibody and biotherapeutic solutions to partners from discovery to IND. T...
2022-11-15 12:19
1348
Nuance Pharma Announces Clearance of IND Application for Respiratory Syncytial Virus (RSV) Vaccine in China
SHANGHAI, Nov. 13, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal phase III clinical trial of MVA-BN RSV vaccine against respiratory syncytial virus (RSV) in a...
2022-11-14 09:54
1396
SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969
State-run financing to provide two-year support of Phase 1 research for oncology candidate, SKL27969, for the potential treatment of advanced solid tumors SK Biopharmaceuticals to present preclinical data on oncology candidate, SKL27969, at Society for Neuro-Oncology Conference PANGYO, South Ko...
2022-11-14 08:00
1657
Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting
- Oral presentation highlights preclinical data with ATG-031, an in-house discovered anti-CD24 monoclonal antibody,tracking to an investigational new drug (IND) filing in H1:2023 - Three poster presentations showcase preclinical data with three programs developed or discovered in-house,ATG-1...
2022-11-11 08:30
1908
CBC-backed ABio-X appoints pharmaceutical and healthcare veteran Dr. Jeffrey Jonas as CEO
WALTHAM, Mass., Nov. 10, 2022 /PRNewswire/ -- ABio-X, the Massachusetts-based biotech incubation platform focused on transformative medicines and breakthrough technologies, today announced the appointment ofJeffrey Jonas, M.D., as its Chief Executive Officer (CEO). Dr. Jonas brings with him mo...
2022-11-10 21:00
1528
Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
SHANGHAI, Nov. 10, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) appl...
2022-11-10 19:02
1530
Week's Top Stories
Most Reposted
SUNRATE announces strategic partnership with Agoda
[Picked up by 192 media titles]
2022-11-24 08:00ZTO Reports Third Quarter 2022 Unaudited Financial Results
[Picked up by 190 media titles]
2022-11-22 06:00China Matters releases a short video "11 Reasons Why I've Fallen in Love with Beijing" to tell an American vlogger's view
[Picked up by 179 media titles]
2022-11-23 03:10Trip.com bookings and app downloads hit new highs during 11.11 global campaign
[Picked up by 178 media titles]
2022-11-24 08:00
China Matters releases a short video "What was considered the 'Ivy League' of ancient China?" to tell a British scholar's view
[Picked up by 160 media titles]
2022-11-24 19:30Most Read
LightInTheBox Reports Third Quarter 2022 Financial Results
2022-11-25 19:00
7816
Over 20,000 international beauty stakeholders made Cosmoprof Asia 2022 in Singapore a resounding success, empowering the industry ahead of next year's return to Hong Kong
2022-11-25 18:25
7242
Sino Land wins the Grand Award at the HKMA Hong Kong Sustainability Award 2022
2022-11-25 18:47
7212
Boqii to Announce Fiscal 2023 First Half Unaudited Financial Results on December 1, 2022
2022-11-25 20:00
7141
SmallRig Introduces 4 Powerful COB LED Video Lights with "AstralTech" Optical System
2022-11-25 20:27
6956